{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:38:39Z","timestamp":1771663119901,"version":"3.50.1"},"reference-count":66,"publisher":"Akademiai Kiado Zrt.","issue":"47","license":[{"start":{"date-parts":[[2023,11,26]],"date-time":"2023-11-26T00:00:00Z","timestamp":1700956800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2023,11,26]]},"abstract":"<jats:p>Az alkoholos m\u00e1jbetegs\u00e9g a m\u00e1jk\u00e1rosod\u00e1s spektrum\u00e1t jelenti a steatosist\u00f3l a\n                    steatohepatitisen \u00e9s fibrosison \u00e1t a cirrhosisig \u00e9s a hepatocellularis\n                    carcinom\u00e1ig. Progresszi\u00f3ja f\u00fcgg az alkoholfogyaszt\u00e1s \u00e9s a m\u00e1jbetegs\u00e9g\n                    s\u00falyoss\u00e1g\u00e1t\u00f3l, valamint kock\u00e1zati t\u00e9nyez\u0151kt\u0151l, mint genetikai hajlam, n\u0151i\n                    fog\u00e9konys\u00e1g, doh\u00e1nyz\u00e1s, elh\u00edz\u00e1s, v\u00edrusinfekci\u00f3. Alkoholos m\u00e1jbeteg eset\u00e9n\n                    val\u00f3j\u00e1ban k\u00e9t k\u00f3rk\u00e9pet kell diagnosztiz\u00e1lni \u00e9s kezelni: egyr\u00e9szt az \u00e1rtalmas\n                    alkoholfogyaszt\u00e1st (alkoholhaszn\u00e1lati zavart), m\u00e1sr\u00e9szt mag\u00e1t a m\u00e1jbetegs\u00e9get,\n                    \u00e9s mindebben els\u0151rend\u0171 fontoss\u00e1g\u00fa az absztinencia el\u00e9r\u00e9se \u00e9s fenntart\u00e1sa.\n                    Mindk\u00e9t k\u00f3r\u00e1llapotra vonatkoz\u00f3an ismertek biomarkerek, nem invaz\u00edv diagnosztikus\n                    tesztek. Az absztinencia el\u00e9r\u00e9s\u00e9ben farmakol\u00f3giai \u00e9s pszichol\u00f3giai intervenci\u00f3k\n                    alkalmazhat\u00f3k, m\u00edg a m\u00e1jbetegs\u00e9g ter\u00e1pi\u00e1j\u00e1ban a f\u0151 c\u00e9lpontok a gyullad\u00e1s \u00e9s az\n                    oxidat\u00edv stressz cs\u00f6kkent\u00e9se, a sejtk\u00e1rosod\u00e1s \u00e9s a fibrosis g\u00e1tl\u00e1sa, a\n                    regener\u00e1ci\u00f3 t\u00e1mogat\u00e1sa \u00e9s a m\u00e1j\u2013b\u00e9l-tengely m\u0171k\u00f6d\u00e9s\u00e9nek helyre\u00e1ll\u00edt\u00e1sa. Az\n                    alkoholos hepatitisben \u00e9s cirrhosisban szenved\u0151 betegek kezel\u00e9se gyakran ig\u00e9nyli\n                    az intenz\u00edv pszichol\u00f3giai-addiktol\u00f3giai t\u00e1mogat\u00e1st, amely a legjobban a\n                    \u201emultidiszciplin\u00e1ris integr\u00e1lt ell\u00e1t\u00e1si modellben\u201d val\u00f3sulhat meg. A\n                    belgy\u00f3gy\u00e1szati (kortikoszteroid-) kezel\u00e9sre nem reag\u00e1l\u00f3 s\u00falyos alkoholos\n                    hepatitises betegek sz\u00e1m\u00e1ra \u2013 gondos szelekci\u00f3t k\u00f6vet\u0151en \u2013 a \u201ekorai\n                    m\u00e1jtranszplant\u00e1ci\u00f3\u201d jelenthet megold\u00e1st. Orv Hetil. 2023; 164(47):\n                    1846\u20131864.<\/jats:p>","DOI":"10.1556\/650.2023.32921","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T14:07:36Z","timestamp":1701094056000},"page":"1846-1864","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":6,"title":["Alkoholos m\u00e1jbetegs\u00e9g \u2013 2023"],"prefix":"10.1556","volume":"164","author":[{"given":"Alajos","family":"P\u00e1r","sequence":"first","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, I. Sz. Belgy\u00f3gy\u00e1szati Klinika P\u00e9cs, Pacsirta u. 1., 7624 Magyarorsz\u00e1g"},{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, II. Sz. Belgy\u00f3gy\u00e1szati Klinika \u00e9s Nephrologiai, Diabetol\u00f3giai Centrum P\u00e9cs Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriella","family":"P\u00e1r","sequence":"additional","affiliation":[{"name":"P\u00e9csi Tudom\u00e1nyegyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Klinikai K\u00f6zpont, I. Sz. Belgy\u00f3gy\u00e1szati Klinika P\u00e9cs, Pacsirta u. 1., 7624 Magyarorsz\u00e1g"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"425","reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cld.2018.09.011","article-title":"Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease","volume":"23","author":"1 Axley","year":"2019","unstructured":"1 Axley PD, Richardson CT, Singal AK. Epidemiology of alcohol consumption and societal burden of alcoholism and alcoholic liver disease. Clin Liver Dis. 2019; 23: 39-50.","journal-title":"Clin Liver Dis"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1111\/add.13757","article-title":"The relationship between different dimensions of alcohol use and the burden of disease - an update","volume":"112","author":"2 Rehm","year":"2017","unstructured":"2 Rehm J, Gmel GE Sr, Gmel G, et al. The relationship between different dimensions of alcohol use and the burden of disease - an update. Addiction 2017; 112: 968-1001.","journal-title":"Addiction"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","article-title":"Burden of liver diseases in the world","volume":"70","author":"3 Asrani","year":"2019","unstructured":"3 Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol. 2019; 70: 151-171.","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"4 Devarbhavi","year":"2023","unstructured":"4 Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol. 2023; 79: 516-537.","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"5 Crabb","year":"2020","unstructured":"5 Crabb DW, Im GY, Szabo G, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2020; 71: 306-333.","journal-title":"Hepatology"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6 European Association for the Study of the Liver. EASL clinical practice guidelines: Management of alcohol-related liver disease. J Hepatol. 2018; 69: 154-181.","DOI":"10.1016\/j.jhep.2018.03.018"},{"key":"ref6","unstructured":"7 Wood AM, Kaptoge S, Butterworth AS, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018; 391: 1513-1523. Erratum: Lancet 2018; 391: 2212."},{"key":"ref7","unstructured":"8 National Institute on Alcohol Abuse and Alcoholism. Alcohol facts and statistics. Available from: https:\/\/www.niaaa.nih.gov\/alcohols-effects-health\/alcohol-topics\/alcohol-facts-and-statistics [accessed: December 19, 2021]."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapsychiatry.2015.0584","article-title":"Results from the National Epidemiologic Survey on Alcohol and Related Conditions III","volume":"72","author":"9 Grant","year":"2015","unstructured":"9 Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 alcohol use disorder. Results from the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry 2015; 72: 757-760.","journal-title":"JAMA Psychiatry"},{"key":"ref9","unstructured":"10 P\u00e1r A, P\u00e1r G. Alcoholic liver disease - 2018: pathogenesis, diagnosis, treatment. [Alkoholos m\u00e1jbetegs\u00e9g - 2018: patogenezis, diagn\u00f3zis, kezel\u00e9s.] Orvostov\u00e1bbk Szle. 2018; 25: 17-28. [Hungarian]"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11 P\u00e1r A, P\u00e1r G. Alcoholic liver disease: the roles of genetic-epigenetic factors and the effect of abstinence. [Alkoholos m\u00e1jbetegs\u00e9g: a genetikai-epigenetikai t\u00e9nyez\u0151k szerepe \u00e9s az absztinencia hat\u00e1sa.] Orv Hetil. 2019; 160: 524-532. [Hungarian]","DOI":"10.1556\/650.2019.31352"},{"key":"ref11","unstructured":"12 Hagym\u00e1si K. Can improve the condition of patients with alcoholic liver disease after abstinence? [Javulhat-e az alkoholos m\u00e1jbeteg \u00e1llapota az absztinenci\u00e1t k\u00f6vet\u0151en?] Orvostov\u00e1bbk Szle. 2018; 25: 29-31. [Hungarian]"},{"key":"ref12","unstructured":"13 Patel PV, Flam SL. Screening, diagnosis and treatment of alcohol-related liver disease and alcohol-associated hepatitis. Gastroenterol Hepatol. 2022; 18: 409-417."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1016\/j.cgh.2023.02.017","article-title":"Alcohol-associated liver disease: integrated management with alcohol use disorder","volume":"21","author":"14 Arab","year":"2023","unstructured":"14 Arab JP, Addolorato G, Mathurin P, et al. Alcohol-associated liver disease: integrated management with alcohol use disorder. Clin Gastronterol Hepatol. 2023; 21: 2124-2134.","journal-title":"Clin Gastronterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15 Smith PC, Schmidt SM, Allensworth-Davies D, et al. Primary care validation of a single-question alcohol screening test. J Gen Intern Med. 2009; 24: 783-788. Erratum: J Gen Intern Med. 2010; 25: 375.","DOI":"10.1007\/s11606-009-0928-6"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1360-0443.1993.tb02093.x","article-title":"Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption II","volume":"88","author":"16 Saunders","year":"1993","unstructured":"16 Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption II. Addiction 1993; 88: 791-804.","journal-title":"Addiction"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17 Mohos A, Varga A, Hargittay Cs, et al. Examination of the health status and health behaviors of Hungarian family physicians. [Magyar csal\u00e1dorvosok eg\u00e9szs\u00e9gi \u00e1llapot\u00e1nak, \u00e9letm\u00f3dj\u00e1nak vizsg\u00e1lata.] Orv Hetil. 2021; 162: 449-457. [Hungarian]","DOI":"10.1556\/650.2021.31971"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.jhep.2022.03.025","article-title":"Therapeutic advances in alcohol-associated hepatitis","volume":"76","author":"Szabo Gy","year":"2022","unstructured":"18 Szabo Gy, Thursz M, Shah VH. Therapeutic advances in alcohol-associated hepatitis. J Hepatol. 2022; 76: 1279-1290.","journal-title":"J Hepatol"},{"key":"ref18","unstructured":"19 Agency for Healthcare Research and Quality. Five major steps to intervention (the \"5 A's\"). Available from: https:\/\/www.ahrq.gov\/professionals\/clinicians-providers\/guidelinesrecommendations\/tobacco\/5steps.html [accessed: November 7, 2018]."},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20 K\u00e1d\u00e1r BK, Prib\u00e9k IK, Gajdics J, et al. Assessment of alcohol withdrawal syndrome: new perspectives. [Az alkoholmegvon\u00e1sos szindr\u00f3ma ell\u00e1t\u00e1sa: \u00faj perspekt\u00edv\u00e1k.] Orv Hetil. 2023; 164: 1487-1496. [Hungarian]","DOI":"10.1556\/650.2023.32847"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jhep.2015.11.006","article-title":"Simple measures have the potential to prevent tens of thousands of premature deaths","volume":"64","author":"Sheron N. Alcohol","year":"2016","unstructured":"21 Sheron N. Alcohol and liver disease in Europe. Simple measures have the potential to prevent tens of thousands of premature deaths. J Hepatol. 2016; 64: 957-967.","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/biomedicines7040099","article-title":"Global burden of alcohol use disorders and alcohol liver disease","volume":"7","author":"Rehm J","year":"2019","unstructured":"22 Rehm J, Shield KD. Global burden of alcohol use disorders and alcohol liver disease. Biomedicines 2019; 7: 99.","journal-title":"Biomedicines"},{"key":"ref22","unstructured":"23 Centers of Disease Control and Prevention. Fact sheet: Preventing Excessive Alcohol Use. Strategies to reduce excessive alcohol use. CDC, Atlanta, GA. 23. 06. 2023."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.35946\/arcr.v42.1.13","article-title":"Alcohol use disorder and alcohol-associated liver disease","volume":"42","author":"Ramkissoon R","year":"2022","unstructured":"24 Ramkissoon R, Shah VH. Alcohol use disorder and alcohol-associated liver disease. Alcohol Res. 2022; 42: 13.","journal-title":"Alcohol Res"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"17562848231170946","DOI":"10.1177\/17562848231170946","article-title":"Therapeutic targets in alcohol-associated liver disease: progress and challenges","volume":"16","author":"25 Adekunle","year":"2023","unstructured":"25 Adekunle AD, Adejumo A, Singal K. Therapeutic targets in alcohol-associated liver disease: progress and challenges. Therap Adv Gastroenterol. 2023; 16: 17562848231170946.","journal-title":"Therap Adv Gastroenterol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.jhep.2023.02.026","article-title":"Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury","volume":"79","author":"26 Hackstein","year":"2023","unstructured":"26 Hackstein CP, Spitzer J, Symeonidis K, et al. Interferon-induced IL-10 drives systemic T-cell dysfunction during chronic liver injury. J Hepatol. 2023; 79: 150-166.","journal-title":"J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1111\/j.1530-0277.1981.tb04890.x","article-title":"Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans","volume":"5","author":"Hrubec Z","year":"1981","unstructured":"27 Hrubec Z, Omenn GS. Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. Alcohol Clin Exp Res. 1981; 5: 207-215.","journal-title":"Alcohol Clin Exp Res"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2","DOI":"10.21037\/tgh.2019.09.06","article-title":"Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD)","volume":"6","author":"Choudhary NS","year":"2021","unstructured":"28 Choudhary NS, Duseja A. Genetic and epigenetic disease modifiers: non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). Transl Gastroenterol Hepatol. 2021; 6: 2.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1030399","DOI":"10.3389\/fgstr.2022.1030399","article-title":"An update on the genetics of alcoholic liver disease","volume":"1","author":"29 Vishnubhotla","year":"2022","unstructured":"29 Vishnubhotla R, Kulkarni AV, Sharma M, et al. An update on the genetics of alcoholic liver disease. Front Gastroenterol. 2022; 1: 1030399.","journal-title":"Front Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30 P\u00e1r A, P\u00e1r G. Advances in the pathogenesis of non alcololic fatty liver disease. [\u00dajabb adatok a nem alkoholos zs\u00edrm\u00e1j patogenezis\u00e9hez.] Orv Hetil. 2017; 158: 882-894. [Hungarian]","DOI":"10.1556\/650.2017.30775"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/j.1465-3362.2009.00153.x","article-title":"Alcohol as risk factor for liver cirrhosis: a systematic review and meta-analysis","volume":"29","author":"31 Rehm","year":"2010","unstructured":"31 Rehm J, Taylor B, Mohapatra S, et al. Alcohol as risk factor for liver cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev. 2010; 29: 437-445.","journal-title":"Drug Alcohol Rev"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/jvh.12399","article-title":"Alcoholic hepatitis and HCV interactions in the modulation of liver disease","volume":"22","author":"32 Punzalan","year":"2015","unstructured":"32 Punzalan CS, Bukong TN, Szabo G. Alcoholic hepatitis and HCV interactions in the modulation of liver disease. J Viral Hepat. 2015; 22: 769-776.","journal-title":"J Viral Hepat"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3109\/00365521.2013.777469","article-title":"Smoking and risk of liver cirrhosis: a population-based cohort study","volume":"48","author":"33 Dam","year":"2013","unstructured":"33 Dam MK, Flensborg-Madsen T, Eliasen M, et al. Smoking and risk of liver cirrhosis: a population-based cohort study. Scand J Gastroenterol. 2013; 48: 585-591.","journal-title":"Scand J Gastroenterol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/apt.13523","article-title":"Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis","volume":"43","author":"34 Kennedy","year":"2016","unstructured":"34 Kennedy OJ, Roderick P, Buchanan R, et al. Systematic review with meta-analysis: coffee consumption and the risk of cirrhosis. Aliment Pharmacol Ther. 2016; 43: 562-574.","journal-title":"Aliment Pharmacol Ther"},{"key":"ref34","unstructured":"35 World Health Organization. Global information system on alcohol and health. WHO, Geneva, 2018. Available from: https:\/\/www.who.int\/data\/gho\/data\/themes\/global-information-system-on-alcohol-and-health [accessed: 7 January, 2022]."},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36 European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2022; 75: 659-689.","DOI":"10.1016\/j.jhep.2021.05.025"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"37 P\u00e1r G. Non-invasive tests for evaluation of the severity and prognosis of liver diseases. [A m\u00e1jbetegs\u00e9gek s\u00falyoss\u00e1g\u00e1nak \u00e9s progn\u00f3zis\u00e1nak nem invaz\u00edv vizsg\u00e1l\u00f3m\u00f3dszerei.] Orv Hetil. 2023; 164: 847-858. [Hungarian]","DOI":"10.1556\/650.2023.32780"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"38 Altamirano J, Miquel R, Katoonizadeh A, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology 2014; 146: 1231-1239.e1-e6.","DOI":"10.1053\/j.gastro.2014.01.018"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1038\/s41591-022-01850-y","article-title":"Noninvasive proteomic biomarkers for alcohol-related liver disease","volume":"28","author":"39 Niu","year":"2022","unstructured":"39 Niu L, Thiele M, Geyer PE, et al. Noninvasive proteomic biomarkers for alcohol-related liver disease. Nat Med. 2022; 28: 1277-1287.","journal-title":"Nat Med"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"40 P\u00e1r A, Hegyi JP, V\u00e1ncsa Sz, et al. Sarcopenia - 2021. Pathophysiology, diagnosis, therapy. [Sarcopenia - 2021. Patofiziol\u00f3gia, diagn\u00f3zis, ter\u00e1pia.] Orv Hetil. 2021; 162: 3-12. [Hungarian]","DOI":"10.1556\/650.2021.32015"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"41 De Franchis R, on behalf of the Baveno VI Faculty. Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015; 63: 743-752.","DOI":"10.1007\/978-3-319-23018-4"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3389\/fphys.2019.01028","article-title":"A diagnostic test accuracy meta-analysis","volume":"10","author":"42 Szak\u00e1cs","year":"2019","unstructured":"42 Szak\u00e1cs Z, Er\u0151ss B, So\u00f3s A, et al. Baveno criteria safely identify patients with compensated advanced chronic liver disease who can avoid variceal screening endoscopy. A diagnostic test accuracy meta-analysis. Front Physiol. 2019; 10: 1028.","journal-title":"Front Physiol"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"43 Ferenci P, Dragosics B, Dittrich H, et al. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol. 1989, 9: 105-113.","DOI":"10.1016\/0168-8278(89)90083-4"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"44 Higuera-de-la-Tijera F, Lira-Vera JE, Morales-Guti\u00e9rrez O, et al. Alcoholic liver disease. Clin Liver Dis. 2022: 19: 63-67.","DOI":"10.1002\/cld.1164"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.livres.2023.03.002","article-title":"Current and emerging therapies for alcohol-associated hepatitis","volume":"7","author":"45 Idalsoaga","year":"2023","unstructured":"45 Idalsoaga F, Ayares G, D\u00edaz LA, et al. Current and emerging therapies for alcohol-associated hepatitis. Liver Res. 2023; 7: 35-46.","journal-title":"Liver Res"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"46 Maddrey","year":"1978","unstructured":"46 Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-199.","journal-title":"Gastroenterology"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"47 Thursz","year":"2015","unstructured":"47 Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med. 2015; 372: 1619-1628.","journal-title":"N Engl J Med"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/gut.2010.224097","article-title":"Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data","volume":"60","author":"48 Mathurin","year":"2011","unstructured":"48 Mathurin P, O'Grady J, Carithers RL, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut 2011; 60: 255-260.","journal-title":"Gut"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"49 Louvet A, Labreuche J, Artru F, et al. Combining data from liver disease scoring systems better predicts outcomes of patients with alcoholic hepatitis. Gastroenterology 2015; 149: 398-406.e8.","DOI":"10.1053\/j.gastro.2015.04.044"},{"key":"ref49","unstructured":"50 National Clinical Trials. Efficacy study of anakinra, pentoxifylline, and zinc compared to methyl-prednisolone in severe acute alcoholic hepatitis. Available from: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT01809132 [accessed: 7 January, 2022]."},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"51 Vergis N, Patel V, Bogdanowicz K, et al. II-1beta signal inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH). J Hepatol. 2022; 77: S34-S35.","DOI":"10.1016\/S0168-8278(22)00480-9"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/hep.31108","article-title":"Final analysis of the phase 2b CENTAUR study","volume":"72","author":"52 Ratziu","year":"2020","unstructured":"52 Ratziu V, Sanyal A, Harison SA, et al. Cenicriviroc treatment for adults with non-alcoholic steatohepatitis and fibrosis. Final analysis of the phase 2b CENTAUR study. Hepatology 2020; 72: 892-905.","journal-title":"Hepatology"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1101214","article-title":"Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis","volume":"365","author":"53 Nguyen-Khac","year":"2011","unstructured":"53 Nguyen-Khac E, Thevenot T, Piquet MA, et al. Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis. N Engl J Med. 2011; 365: 1781-1789.","journal-title":"N Engl J Med"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"54 Singh S, Murad MH, Chandar AK, et al. Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis. Gastroenterology 2015; 149: 958-970.e12.","DOI":"10.1053\/j.gastro.2015.06.006"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.3748\/wjg.v21.i16.4975","article-title":"Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis","volume":"21","author":"55 Higuera-de la Tijera","year":"2015","unstructured":"55 Higuera-de la Tijera F, Serv\u00edn-Caama\u00f1o AI, Serralde-Z\u00fa\u00f1iga AE, et al. Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis. World J Gastroenterol. 2015; 21: 4975-4985.","journal-title":"World J Gastroenterol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"56 Arab","year":"2020","unstructured":"56 Arab JP, Sehrawat TS, Simonetto DA, et al. An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis. Hepatology 2020; 72: 441-453.","journal-title":"Hepatology"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1038\/ajg.2014.154","article-title":"Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study","volume":"109","author":"57 Singh","year":"2014","unstructured":"57 Singh V, Sharma AK, Narasimhan RL, et al. Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study. Am J Gastroenterol. 2014; 109: 1417-1423.","journal-title":"Am J Gastroenterol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"100139","DOI":"10.1016\/j.jhepr.2020.100139","article-title":"Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials","volume":"2","author":"58 Marot","year":"2020","unstructured":"58 Marot A, Singal AK, Moreno C, et al. Granulocyte colony-stimulating factor for alcoholic hepatitis: a systematic review and meta-analysis of randomised controlled trials. JHEP Rep. 2020; 2: 100139.","journal-title":"JHEP Rep"},{"key":"ref58","unstructured":"59 Hassanein T, Stein LL, Flamm SL, et al. Safety and efficacy of DUR-928: a potential new therapy for acute alcoholic hepatitis. Hepatology 2019; 70: 1483A-1484A."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.jceh.2022.01.001","article-title":"Long-term outcomes of stool transplant in alcohol-associated hepatitis - analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care","volume":"12","author":"60 Philips","year":"2022","unstructured":"60 Philips CA, Ahamed R, Rajesh S, et al. Long-term outcomes of stool transplant in alcohol-associated hepatitis - analysis of clinical outcomes, relapse, gut microbiota and comparisons with standard care. J Clin Exp Hepatol. 2022; 12: 1124-1132.","journal-title":"J Clin Exp Hepatol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/hep.31496","article-title":"A randomized clinical trial of fecal microbiota transplant for alcohol use disorder","volume":"73","author":"61 Bajaj","year":"2021","unstructured":"61 Bajaj JS, Gavis EA, Fagan A, et al. A randomized clinical trial of fecal microbiota transplant for alcohol use disorder. Hepatology 2021; 73: 1688-1700.","journal-title":"Hepatology"},{"key":"ref61","unstructured":"62 De Franchis R, Bosch J, Garcia-Tsao G, et al. BavenoVII. Renewing consensus in portal hypertension. J Hepatol 2022; 76: 959-974. Erratum: J Hepatol. 2022. Apr. 14. PMID 35120736."},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"63 Caraceni P, Abraldes JG, Gin\u00e8s P, et al. The search for disease-modifying agents in decompensated cirrhosis: from drug repurposing to drug discovery. J Hepatol. 2021; 75(Suppl 1): S118-S134.","DOI":"10.1016\/j.jhep.2021.01.024"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1056\/NEJMoa1105703","article-title":"Early liver transplantation for severe alcoholic hepatitis","volume":"365","author":"64 Mathurin","year":"2011","unstructured":"64 Mathurin P, Moreno C, Samuel D, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med. 2011; 365: 1790-1800.","journal-title":"N Engl J Med"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/SLA.0000000000001831","article-title":"Three-year results of a pilot program in early liver transplantation for severe alcoholic hepatitis","volume":"265","author":"65 Lee","year":"2017","unstructured":"65 Lee BP, Chen PH, Haugen C, et al. Three-year results of a pilot program in early liver transplantation for severe alcoholic hepatitis. Ann Surg. 2017; 265: 20-29.","journal-title":"Ann Surg"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1016\/j.jhep.2023.03.007","article-title":"Early liver transplantation for severe acute alcohol-related hepatitis after more than a decade of experience","volume":"78","author":"66 Germani","year":"2023","unstructured":"66 Germani G, Mathurin P, Lucey MR, et al. Early liver transplantation for severe acute alcohol-related hepatitis after more than a decade of experience. J Hepatol. 2023; 78: 1130-1136.","journal-title":"J Hepatol"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/47\/article-p1846.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/47\/article-p1846.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/akjournals.com\/downloadpdf\/journals\/650\/164\/47\/article-p1846.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T07:57:15Z","timestamp":1723190235000},"score":1,"resource":{"primary":{"URL":"https:\/\/akjournals.com\/view\/journals\/650\/164\/47\/article-p1846.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,26]]},"references-count":66,"journal-issue":{"issue":"47"},"URL":"https:\/\/doi.org\/10.1556\/650.2023.32921","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,26]]}}}